DOI QR코드

DOI QR Code

DENTAL TREATMENT IN A PATIENT WITH FUKUYAMA TYPE MUSCULAR DYSTROPHY UNDER TOTAL INTRAVENOUS ANESTHESIA USING PROPOFOL

후쿠야마 선천성 근이영양증 환자의 프로포폴을 이용한 전정맥마취 하 치과치료

  • Jin, Dallae (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Shin, Teo-Jeon (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Hyun, Hong-Keun (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Kim, Young-Jae (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Kim, Jung-Wook (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Lee, Sang-Hoon (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Kim, Chong-Chul (Department of Pediatric Dentistry, School of Dentistry, Seoul National University) ;
  • Jang, Ki-Taeg (Department of Pediatric Dentistry, School of Dentistry, Seoul National University)
  • 진달래 (서울대학교 치의학대학원 소아치과학교실) ;
  • 신터전 (서울대학교 치의학대학원 소아치과학교실) ;
  • 현홍근 (서울대학교 치의학대학원 소아치과학교실) ;
  • 김영재 (서울대학교 치의학대학원 소아치과학교실) ;
  • 김정욱 (서울대학교 치의학대학원 소아치과학교실) ;
  • 이상훈 (서울대학교 치의학대학원 소아치과학교실) ;
  • 김종철 (서울대학교 치의학대학원 소아치과학교실) ;
  • 장기택 (서울대학교 치의학대학원 소아치과학교실)
  • Received : 2012.06.04
  • Accepted : 2012.12.18
  • Published : 2013.02.28

Abstract

Muscular dystrophy is a genetically heterogeneous group of disorders characterized by progressive muscle weakness of variable distribution and severity. Fukuyama type congenital muscular dystrophy (FCMD) is an unusual form of muscular dystrophy with autosomal recessive inheritance and is clinically characterized by an early age of onset, severe central nervous system involvement, facial muscle weakness, and multiple joint contractures. Muscular dystrophy is susceptible to perioperative respiratory, cardiac and other complications. Patients with FCMD have upper airway muscle weakness, therefore general anesthesia is preferred to sedation regarding maintaining the airway when treating these patients. The development of malignant hyperthermia in general anesthesia for patients with muscular dystrophy is a concern. Total intravenous anesthesia should be used instead of inhaled anesthetics because of the risk of malignant hyperthermia. A 3-year-9-month old, 13kg girl with Fukuyama type congenital muscular dystrophy was scheduled for dental treatment under general anesthesia. She had multiple caries and 14 primary teeth needed caries treatment. Prior to general anesthesia, oral premedication with 9 mg midazolam was given. General anesthesia was induced and maintained with target controlled infusion of propofol $3{\sim}3.5{\mu}g/mL$. The patient with progressive muscular dystrophy was successfully treated under total intravenous anesthesia with a target controlled infusion of propofol. There were no complications related to anesthesia and dental treatment during or after the operation. This case suggests that target controlled infusion of propofol is a safe and appropriate anesthetic technique in FCMD patients for dental treatment.

근이영양증은 점진적인 근육 약화를 특징으로 하는 유전질환이다. 그 중 후쿠야마 선천성 근이영양증은 상염색체 열성으로 유전되며, 영아기 초기부터 시작되어 중추신경계, 안면근 등에도 이환되고 다발성 관절구축도 나타난다. 근이영양증 환자는 호흡기계나 심장 등의 합병증 발생 위험이 있으며, 특히 흡입마취제를 이용한 전신마취 시 악성고열증 가능성이 문제가 된다. 본 증례에서는 후쿠야마 선천성 근이영양증을 가진 3세 9개월 여아의 다발성 우식증을 전정맥마취 하에 치료하였다. 전신마취 유도 및 유지를 위해 프로포폴을 효과처 농도 $3{\sim}3.5{\mu}g/mL$, 진통 효과를 위해 레미펜타닐을 1.5 ng/mL 목표농도 조절주입하였다. 적절한 마취 심도와 안정적인 생징후를 유지하며 합병증 발생없이, 후쿠야마 선천성 근이영양증 환아의 전정맥마취하 다발성 치아우식 치료가 성공적으로 이루어져 이를 보고하고자 한다.

Keywords

References

  1. Fukuyama Y, Kawazura M, Haruna H : A peculiar form of congenital progressive muscular dystrophy. Paediatr Univ Tokyo, 4:5-8, 1960.
  2. T. Toda, K. Kobayashi, E. Kondo-Iida, et al. : The Fukuyama congenital muscular dystrophy story. Neuromuscular Disorders, 10:153-159, 2000. https://doi.org/10.1016/S0960-8966(99)00109-1
  3. Osawa M, Sumida S, Suzuki N, et al. : Fukuyama type congenital muscular dystrophy. In : Fukuyama Y, Osawa M, Saito K, eds. Congenital Muscular Dystrophies. Amsterdam Netherlands: Elsevier Science, 31-68, 1997.
  4. National Center for Biotechnology Information (NCBI): Gene Reviews by title: Fukuyama Congenital Muscular Dystrophy. http://www.ncbi.nlm.nih.gov/books/NBK1206/(Accessed May 14 2012)
  5. Kiichi Arahata : Muscular dystrophy. Neuropathology, 20:S34-S41, 2000. https://doi.org/10.1046/j.1440-1789.2000.00321.x
  6. Toda T : Fukuyama-type congenital muscular dystrophy. Rinsho Shinkeigaku, 40:1297-1299, 2000.
  7. K. Kobayashi, Y. Nakahori, M. Miyake, et al. : An ancient retrotransposal insertion causes Fukuyamatype congenital muscular dystrophy. Nature, 394:388-392, 1998. https://doi.org/10.1038/28653
  8. Fumiaki Saito, Kiichiro Matsumura : Fukuyamatype congenital muscular dystrophy and defective glycosylation of ${\alpha}$-dystroglycan. Skeletal Muscle, 1:22, 2011. https://doi.org/10.1186/2044-5040-1-22
  9. Kawaai et al. : Continuous infusion propofol general anesthesia for dental treatment in patients with progressive muscular dystrophy. Anesth Prog, 54:12- 16, 2005.
  10. Gurnaney H, Brown A, Litman RS : Malignant hyperthermia and muscular dystrophies. Anesth Analg, 109:1043-1048, 2009. https://doi.org/10.1213/ane.0b013e3181aa5cf6
  11. Gerald V, Robin G : Inhalation anesthetics and Duchenne’s muscular dystrophy. Can J Anaesth, 46:525-528, 1999. https://doi.org/10.1007/BF03013541
  12. Chalkiadis GA, Branch KG : Cardiac arrest after isoflurane anesthesia in a patient with Duchenne’s muscular dystrophy. Anaesthesia, 45:22-25, 1990. https://doi.org/10.1111/j.1365-2044.1990.tb14497.x
  13. Sethna NF, Rockhoff MA : Cardiac arrest following inhalation induction of anaesthesia in child with Duchenne’s muscular dystrophy. Can Anaesth Soc J, 33:799-802, 1986. https://doi.org/10.1007/BF03027134
  14. Larsen UT, Juhl B, Hein-Sorensen O, de Fine Olivarius B : Complications during anaesthesia in patients with Duchenne’s muscular dystrophy (a retrospective study). Can J Anaesth, 36:418-422, 1989. https://doi.org/10.1007/BF03005341
  15. Josie K. Kozack, Donna L. MacIntyre : Malignant hyperthermia. Phys Ther, 81:945-951, 2001.
  16. T. Toda, M. Segawa, Y. Nomura, et al. : Localization of a gene for Fukuyama type congenital musculardystrophy to chromosome 9q31-33. Nature Genet, 5:283-286, 1993. https://doi.org/10.1038/ng1193-283
  17. Heiman-Patterson TD : Neuroleptic malignant syndrome and malignant hyperthermia: important issues for the medical consultant. Med Clin North Am, 77:477-492, 1993. https://doi.org/10.1016/S0025-7125(16)30265-6
  18. Halsall PJ, Hopkins PM : "Malignant hyperthermia". Continuing Education in Anaethesia, Critical Care and Pain, 3;5-9, 2003. https://doi.org/10.1093/bjacepd/mkg002
  19. Poels PJE, Gabreels FJM : Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg, 95:175-192, 1993. https://doi.org/10.1016/0303-8467(93)90122-W
  20. Enzmann NR, Balog EM, Gallant EM : Malignant hyperthermia : effects of sarcoplasmic reticulum $Ca^{2+}$ pump inhibition. Muscle Nerve, 21:361-366, 1998. https://doi.org/10.1002/(SICI)1097-4598(199803)21:3<361::AID-MUS10>3.0.CO;2-2
  21. Yemen TA, McClain C : Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Paediatr Anaesth, 16:105-108, 2006. https://doi.org/10.1111/j.1460-9592.2005.01801.x
  22. Fruen BR, Mickelson JR, Roghair TJ, et al. : Effects of propofol on $Ca^{2+}$ regulation by malignant hyperthermia- susceptible muscle membranes. Anesthesiology, May;82:1274-82, 1995. https://doi.org/10.1097/00000542-199505000-00023
  23. Wikipedia: Propofol. http://en.wikipedia.org/wiki/Propofol (Accessed May 14 2012)
  24. Kim DW : Target controlled infusion. J Korean Med Assoc, 46:454-460, 2003. https://doi.org/10.5124/jkma.2003.46.5.454
  25. Wilson G : Target controlled infusion anaesthesia in children. S Afr J Anaesthesiol Analg, 16:124-126, 2010.